Related Experiment Video
Updated: Aug 8, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
Coronary artery bypass grafting in patients with severe left ventricular dysfunction--early and mid-term outcomes
Oz M Shapira1, Curtis T Hunter, Elad Anter
1Department of Cardiothoracic Surgery, Boston Medical Center, Boston, Massachusetts, USA. oz.shapira@bmc.org
Insights
Coronary artery bypass grafting (CABG) is safe for patients with severe left ventricular dysfunction (LVD), showing low mortality despite higher complication rates. CABG offers effective therapy for ischemic heart disease in patients with low ejection fraction.
Area of Science:
- Cardiology
- Cardiac Surgery
- Medical Outcomes Research
Background:
- Increasing prevalence of severe left ventricular dysfunction (LVD) in patients referred for coronary artery bypass grafting (CABG).
- Need to assess the safety and efficacy of CABG in this high-risk patient population.
Purpose of the Study:
- To evaluate the outcomes of isolated CABG in patients with severe LVD (LVEF ≤ 30%).
- Compare outcomes between patients with severe LVD and those with higher ejection fraction (HEF).
Main Methods:
- Retrospective analysis of 115 consecutive patients with severe LVD undergoing isolated CABG (1995-2000).
- Comparison with 2335 HEF patients.
- Subgroup analysis of LVD patients based on LVEF.
- Prospective data collection via the Society of Thoracic Surgeons database.
Main Results:
- Severe LVD patients had higher comorbidity rates but similar operative mortality and stroke incidence compared to HEF patients.
- Significantly higher rates of respiratory, renal, and vascular complications in the LVD group, leading to longer hospital stays.
- Mid-term survival rates were 91% at 3 years and 76% at 5 years.
- Independent predictors of mortality in LVD patients included female gender, renal failure, respiratory complications, and mitral regurgitation.
Conclusions:
- CABG in severe LVD patients demonstrates low mortality, comparable to HEF patients, but with increased morbidity and length of stay.
- Low ejection fraction itself is not a predictor of hospital mortality.
- CABG is a safe and effective treatment for ischemic heart disease in patients with low ejection fraction.
- Consider mitral valve repair/replacement for moderate mitral regurgitation during CABG.
Background:
The prevalence of patients with severe left ventricular dysfunction (LVD) referred for coronary artery bypass grafting (CABG) is increasing. The aim of the present study was to assess the outcomes of patients with severe LVD undergoing CABG.
Methods:
Outcomes of 115 consecutive patients with severe LVD (left ventricular ejection fraction [LVEF]= 30%, mean 22 +/- 6%) undergoing isolated CABG between 1995 and 2000 were compared to 2335 patients with LVEF >30% (HEF). To further evaluate the LVD patients, they were divided into three subgroups base on LVEF: 0% to 10%, 11% to 20%, and 21% to 30%. Data were collected prospectively and entered into the departmental database of the Society of Thoracic Surgeons.
Results:
Patients in the LVD group had increased incidence of diabetes, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, prior myocardial infarction (MI), congestive heart failure, and less elective procedures compared to the HEF group. Despite this greater risk profile, operative mortality (LVD 2.6% vs. HEF 1.2%, p = 0.19), the incidence of stroke (2.6% vs. 1.0%, p = 0.13), and perioperative MI (0.9% vs. 0.7%) were not statistically different between the groups. The incidence of respiratory (14.8% vs. 1.9%, p < 0.001), renal (5.2% vs. 1.0%, p < 0.001), and vascular (5.2% vs. 0.5%, p < 0.001) complications was significantly higher in the LVD group, resulting in a longer hospital length of stay (8 +/- 8 vs. 6 +/- 4 days, p < 0.0001). In a multivariate analysis, advanced age was as an independent predictor of hospital mortality. Average follow-up in 108 (94%) LVD patients was 36 +/- 22 months (range 2 to 78 months). Twenty-one patients expired during the follow-up, for nine the causes were cardiac-related. Three- and 5-year survival rates were 91 +/- 3% and 76 +/- 6%, respectively. Independent predictors of mid-term mortality in the LVD group by a multivariate analysis included female gender, renal failure, respiratory complications, and grade I/II mitral regurgitation (MR). At the time of follow-up, 72% of LVD patients were in functional class I/II. There were no statistically significant differences in short- and mid-term outcomes among the LVD subgroups.
Conclusion:
CABG in patients with severe LVD can be performed with a low mortality, albeit with higher morbidity and longer length of hospital stay, than patients with LVEF >30%. Low ejection fraction per se was not a predictor of hospital mortality. CABG should be considered a safe and effective therapy for low ejection fraction patients with ischemic heart disease. Mitral valve repair/replacement in the presence of moderate degree of MR should be considered at the time of the initial operation.
More Related Videos
13:10Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery (ALCAPA)
Published on: April 24, 2017
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management